N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need.
N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.
N4 has two proprietary platform delivery system technologies allowing it to improve a drug’s performance, the first using co-crystals to improve a drug’s solubility and the second a delivery system to improve cellular uptake of vaccines.s.
Its first product in development is a 'faster acting' version of Sildenafil (Viagra) reducing the onset of action from one hour to fifteen minutes and improving the performance of the drug in lower acidic conditions.
In addition N4 also offers its Cocrys® service (the only process able to use Hot Melt Extrusion to manufacture co-crystals) and its Nuvac® technology to pharmaceutical companies with their own molecules that have issues with solubility or vaccine performance and need a commercially robust process to help take them into clinical trials.